F. Kudrik

发表

A Phase II Randomized, Double‐Blind, Placebo‐Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First‐Line Treatment of Pancreatic Adenocarcinoma

A. Benson, J. Hecht, Z. Wainberg, 2017, The oncologist.

Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies.

D. Esseltine, A. Ivanova, B. Mitchell, 2005, Blood.

Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal cancer after disease progression on first-line irinotecan-based therapy.

J. Bendell, T. Alcindor, P. Tang, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Hypersensitivity pneumonitis in advanced non-small-cell lung cancer patients receiving gemcitabine and paclitaxel: report of two cases and a review of the literature.

M. Socinski, P. Molina, S. Maygarden, 2002, Clinical lung cancer.

Phase II study of gemcitabine and bevacizumab as first-line treatment in taxane-pretreated, HER2-negative, locally recurrent or metastatic breast cancer.

C. Obasaju, J. Reeves, Michael Jones, 2012, Clinical breast cancer.

TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer

J. Hainsworth, L. Bosserman, H. Burris, 2017, Breast Cancer Research and Treatment.

A Single-Arm, Open-Label, Expanded Access Study of Vemurafenib in Patients With Metastatic Melanoma in the United States

G. Linette, J. Hainsworth, K. Flaherty, 2014, Cancer journal.

Phase II trial of preoperative pemetrexed plus carboplatin in patients with stage IB-III nonsquamous non-small cell lung cancer (NSCLC).

J. Hainsworth, H. Burris, D. Spigel, 2018, Lung cancer.

Phase 1/2 Study of the CD56‐Targeting Antibody‐Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small‐Cell Lung Cancer Patients With Extensive‐Stage Disease

M. Socinski, F. Kaye, P. Ellis, 2017, Clinical lung cancer.

Catastrophic antiphospholipid antibody Syndrome

S. Moll, F. Kudrik, D. B. Thomas, 2003, American journal of hematology.

618PDA PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY OF SIMTUZUMAB OR PLACEBO IN COMBINATION WITH GEMCITABINE FOR THE FIRST LINE TREATMENT OF PANCREATIC ADENOCARCINOMA.

A. Benson, Z. Wainberg, J. Bendell, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

The burden of blood transfusion: a utilization and economic analysis – a pilot study in patients with chemotherapy-induced anemia (CIA)

S. Shreay, Arletta van Breda, J. Reitan, 2013, Journal of medical economics.

A Phase II Randomized, Double‐Blind, Placebo‐Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First‐Line Treatment of Pancreatic Adenocarcinoma

Z. Wainberg, J. Bendell, Hua Dong, 2017, The oncologist.

The burden of blood transfusion: a utilization and economic analysis – a pilot study in patients with chemotherapy-induced anemia (CIA)

S. Shreay, Arletta van Breda, J. Reitan, 2013, Journal of medical economics.

A single-arm, open-label, U.S. expanded access study of vemurafenib in patients with metastatic melanoma.

G. Linette, J. Hainsworth, K. Flaherty, 2012 .